HEMATOLOGIC MALIGNANCIES /ONCOLOGY

The management of patients with hematological malignancies relies on genetic testing that informs diagnosis and prognosis, predicts response to treatment, and measures minimal residual disease. Cytogenetic, molecular cytogenetic and molecular genetic methods should be used together appropriately. Cytogenetic tests reveal the initial state of numerical and structural changes in chromosomes. Molecular cytogenetic tests aim to reach results quickly for specific regions that will affect the diagnosis and treatment of the disease. While molecular tests such as braf, nras, kras are evaluated in solid (organ) cancers, examinations such as FLT3, ITD in hematological cancers have an important place in the prediction of treatment and prognosis.                                                                                                                                                          

FAMILY CANCER SYNDROMES

It is extremely important to reveal the genetic diagnosis in patients with a family history of cancer, to perform recommended cancer screenings on time, to diagnose early and to prevent the transmission of this disorder to the next generations with preimplantation genetic diagnosis. For this purpose, a family tree should be drawn and appropriate genetic testing should be planned according to the type of cancer in the family and the age of onset, and the results should be shared with genetic counseling.